The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 47%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
InMed Pharmaceuticals Inc INM
Outside both standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.
read at $1.52
InMed Pharmaceuticals Inc holds its Markdown at $1.52.
- PHPhase · the trend structure carries the Markdown label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · does not pass the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markdown · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 11 days |
| Price | $1.52 |
| Valuation | N/A trailing · -0.24 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.96 |
The business, in plain words · what the numbers mean
| Forward P/E | -0.2x |
| Profit margin | -172.2% currently unprofitable |
| Return on equity | -112.6% not currently earning a positive return on equity |
| Debt to equity | 0.06 minimal debt — a conservative balance sheet |
| Current ratio | 3.12 comfortably covers its short-term bills |
| Beta | 0.96 steadier than the market |
| Market cap | $8M |
| Employees | 13 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Canada and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in INM's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 47%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The political ledger · congressional disclosures
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 6 May2026 | Ro Khanna | Democrat | sell | 1K–15K |
| 27 Mar2026 | Alan Armstrong | Republican | buy | 1K–15K |
| 21 Jul2026 | April McClain Delaney | Democrat | sell | 1K–15K |
| 2026-04-21 | Ro Khanna | Democrat | Sale | 1K–15K |
| 2026-04-20 | Ro Khanna | Democrat | Sale | 15K–50K |
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.62 | +135.1% | · | $2,351 | +135.1% |
| 2 months | $0.72 | +103.9% | · | $2,039 | +103.9% |
| 3 months | $0.80 | +82.5% | · | $1,825 | +82.5% |
| 6 months | $1.39 | +5.0% | · | $1,050 | +5.0% |
| 1 year | $2.77 | -47.3% | · | $527 | -47.3% |
| 2 years | $4.94 | -70.5% | · | $296 | -70.5% |
| 3 years | $26.00 | -94.4% | · | $56 | -94.4% |
| 5 years | $1,420.00 | -99.9% | · | $1 | -99.9% |
Historical returns from market close data. Past performance does not guarantee future results.